Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) – 2019 to 2024

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: May 28, 2019
Clear
SKU: GMS1197 Category:

The market for cancer/tumor profiling is expected to reach USD 12.35 billion by 2024, growing at 10.42 percent CAGR. Growth in this market is driven by the rising worldwide incidence of cancer and the growing use of biomarkers in tumor profiling.

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 1

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 2

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 3

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 4

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 5

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 6

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 7

Cancer/Tumor Profiling Market by Technology (PCR, In Situ Hybridization, Immunoassay, NGS), Cancer Type (Lung, Breast, Colorectal), Application (Diagnostics, Prognostics), Biomarker Type (Protein Biomarkers, Genomic Biomarkers) - 2019 to 2024 8

1 Global Cancer/Tumor Profiling Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Cancer/Tumor Profiling Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Cancer/Tumor Profiling Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Cancer/Tumor Profiling Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Cancer/Tumor Profiling Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Cancer/Tumor Profiling Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Cancer/Tumor Profiling Market – By Technology (Market Size – & million/billion)
8.1 Immunoassays
8.2 Next Generation Sequencing (NGS)
8.3 Polymerase Chain Reaction (PCR)
8.4 In-Situ Hybridization (ISH)
8.5 Mass Spectrometry
8.6 Others

9 Global Cancer/Tumor Profiling Market – By Cancer Type
9.1 Breast Cancer
9.2 Lung Cancer
9.3 Colorectal Cancer
9.4 Prostate Cancer
9.5 Other

10 Global Cancer/Tumor Profiling Market – By Biomarker Market
10.1 Genetic Biomarkers
10.2 Protein Biomarkers
10.3 Other

11 Global Cancer/Tumor Profiling Market – By Application
11.1 Research
11.2 Clinical

12 Global Cancer/Tumor Profiling Market – By Geography (Market Size – & million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa

13 Global Cancer/Tumor Profiling Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships

14 Global Cancer/Tumor Profiling Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 Illumina, Inc.
14.3 Helomics Corporation
14.4 Genomic Health, Inc.
14.5 Caris Life Sciences
14.6 Qiagen N.V.
14.7 Neogenomic Laboratories, Inc.
14.8 Sysmex Corporation
14.9 HTG Molecular Diagnostics, Inc.
14.10 Nanostring Technologies, Inc.
14.11 Guardant Health, Inc.
14.12 Company 11 & more

15 Global Cancer/Tumor Profiling Market – Appendix
15.1 Sources
15.2 Abbreviations